Lansoprazole-Induced Microscopic Colitis Mimicking Anticancer Drug-Related Diarrhea During Lenvatinib and Pembrolizumab Combination Therapy: A Case Report
Abstract
Persistent diarrhea during anticancer therapy may not be attributable to anticancer agents. Our patient presented with diarrhea during lenvatinib-pembrolizumab therapy, likely caused by lansoprazole-induced microscopic colitis. Even when symptoms closely resemble anticancer drug or immune-related colitis, drug-induced colitis due to concomitant medications, including proton pump inhibitors, should be considered.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.